 Pardes Biosciences Incs NASDAQ: PRDS has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Conference on Retroviruses and Opportunistic Infections CROI 2022. The presentation shared details around the nonclinical profile of PBI-0451 and interim clinical safety, tolerability, and pharmacokinetics PK after single- and multiple ascending doses. 